Abstract 1746P
Background
On-call work is an inherent component of Oncology care. Managerial models focus on length of stay in calculating efficiency within hospitals. Ensuring compliance with the European Working Time Directives (EWTD) for doctors is a legal requirement for Hospitals. Calculations of required physician staff to provide overnight care is not necessarily based on numbers of patients to be cared for, nor the complexity of care. The acute oncology service (AOS) after-hours has to date been provided by the day-time medical team in whole. To improve safety and quality of the AOS for patients being seen after hours, as well as to comply with the EWTD, a change to shift-work for the 1st-on-call oncology doctor is planned in 7/23. We sought to quantify the impact on the service.
Methods
The numbers of non-consultant hospital doctors (NCHDs), with allowances for full staff and also allowing for annual and educational leave entitlements were gathered for 1) pre-shift work implementation and 2) post-implementation of shift work. The number of NCHDs multiplied by the hours available to the ambulatory services (day unit and outpatient clinics) were calculated per week for both service structures to produce the "available NCHD hours".
Results
Assuming the normal working day is 8am to 5pm, this change would result in the reduction of available NCHDs to the ambulatory oncology service from 270 available NCHD hours per week to 171 available NCHD hours once vacation and study leave are factored into the equation, despite the addition of one NCHD to the medical oncology team. This represents a 36% reduction in available staff yet with a likely continued increase in patient activity.
Conclusions
While modifying the after-hours service to shift-work augments availability of medical staff for the acutely unwell patient with cancer and achieves compliance with EWTD, it reduces the numbers of doctors available for a significant part of the day, placing more strain on those doctors trying to manage a similar number of patients in a safe and patient-focused manner. Changes to the after-hours service inadvertently has knock-on effects on the “Oncology Ecosystem” and may impact on future service quality. Adjustments to NCHD numbers to cover the predicted significant staff fall short of those required.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Beaumont RCSI Cancer Centre.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1757P - A real-world evaluation of the effectiveness of thermogram along with clinical breast examination in community-based breast cancer screening program
Presenter: Rahul Ravind
Session: Poster session 23
1758P - Body composition meets precision medicine: The prognostic value of sarcopenia in patients (pt) treated with Molecularly Targeted Agents (MTA)
Presenter: Cinta Hierro
Session: Poster session 23
1760P - Systematic review of quality of life (QoL) inclusion among endpoints, reporting and impact of QoL results in phase III non-inferiority trials of systemic treatments in oncology
Presenter: Jessica Paparo
Session: Poster session 23
1761P - Incidence of herpes zoster in cancer patients in Europe: A systematic review
Presenter: Inga Posiuniene
Session: Poster session 23
1762P - Are published data up-to-date? Analysis of time to publication in major oncological journals
Presenter: Pawel Sobczuk
Session: Poster session 23
1763P - The challenge for Cancer Trials Ireland (CTI) to sponsor NCI and non-EU sponsored trials in the EU
Presenter: Eibhlin Mulroe
Session: Poster session 23
1886P - Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)
Presenter: Craig Gedye
Session: Poster session 23
1887P - Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: Results from the phase III SWOG S0931 (EVEREST) trial
Presenter: Primo Lara
Session: Poster session 23
1888P - 24-month follow up of durvalumab and savolitinib combination in MET-driven clear cell and non-clear cell renal cancer
Presenter: Francesca Jackson-Spence
Session: Poster session 23